George Cardoza - 18 Mar 2026 Form 3 Insider Report for SOPHiA GENETICS SA (SOPH)

Role
Chief Financial Officer
Signature
/s/ Elimara Brunetto as Attorney-in-Fact for George Cardoza
Issuer symbol
SOPH
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 09:46:03 UTC
Previous filing
03 Mar 2022
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CARDOZA GEORGE Chief Financial Officer C/O SOPHIA GENETICS INC., 401 PARK DRIVE, FLOOR 5, BOSTON /s/ Elimara Brunetto as Attorney-in-Fact for George Cardoza 18 Mar 2026 0001518734

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SOPH Ordinary Shares 185,632 18 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 183,333 $3.40 Direct F2
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 187,500 $3.29 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 70,826 ordinary shares issuable upon settlement of two restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 28,388 ordinary shares from a December 18, 2024 grant vesting in equal quarterly installments through December 18, 2028; and (ii) 42,438 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
F2 The share option vests and becomes exercisable as to 25% of the ordinary shares on December 18, 2025, and then in equal monthly installments through December 18, 2028.
F3 The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney